Orencia (abatacept) Injectable Medication Precertification Request
Customize your policy alerts
Sign up for all Aetna policy alerts
Know when Aetna releases new policies or updates existing guidance.
Monitor payer policy activity
Precertification request form for Orencia (abatacept) injectable medication to collect patient, prescriber, clinical, dispensing, dosing, diagnosis, and justification information needed for Aetna prior authorization review. Used for start or continuation of therapy across multiple labeled and off-label indications.
No material clinical or coverage changes were identified for this precertification form.
Policy summary and purpose
This is Aetna's Orencia (abatacept) Injectable Medication Precertification Request form used to collect the patient, prescriber, dispensing, product/dosing, diagnosis, and clinical justification information needed to evaluate medical necessity for start or continuation of therapy across multiple labeled and off‑label indications including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (pJIA), prophylaxis of acute graft versus host disease (GVHD), chronic GVHD, and immune checkpoint inhibitor‑related toxicity. The form captures administrative details (insurance/member and prescriber credentials), dosing (loading and maintenance dose/frequency), place of administration/dispensing and administration CPT codes, and prompts for continuation or start dates as part of the precertification process.
Required clinical information captured on the precertification form
Key numeric thresholds and dosing checks referenced on form
Coding fields requested on the form
| No codes listed |
| No codes listed |
Report administration CPT codes if applicable
When infusion or other administration occurs, include the appropriate administration CPT codes on the precertification form in the Administration code(s) (CPT) field; list any administration CPT codes requested on the form when applicable.
- Administration CPT codes requested on form
- Include codes when infusion/administration occurs
What providers must do when submitting the form
Complete all form fields for precertification review
Provide and legibly complete all required patient, insurer, prescriber, dispensing, product, diagnosis, and clinical fields on the precertification form to allow Aetna to review medical necessity.
- Patient (demographics, weight, height, allergies, contact)
- Insurer (Aetna Member ID, group, other coverage, Medicare/Medicaid IDs)
- Prescriber (credentials, address, phone/fax, NPI, specialty)
- Dispensing/provider and place of administration details
- Product (requested drug, dose, frequency)
- Diagnosis (primary/secondary/other ICD codes)
- Clinical information required for the indication
Precertification submission required
Submit precertification requests to Aetna Precertification Notification by phone or fax; Medicare Advantage Part B requests must use the Medicare request form.
- Phone: 1-866-752-7021
- Fax: 1-888-267-3277
- Medicare Advantage Part B: use Medicare request form
Indication-specific supporting documentation
Provide indication-specific supporting documentation such as prior therapy trials (for example methotrexate, NSAIDs, corticosteroids), evidence of intolerance or contraindication to prior agents, specialist consultation notes, tuberculosis testing results (PPD, IGRA, chest x-ray) when relevant, and dosing rationale consistent with compendia or current literature.
- Prior therapy trials and outcomes
- Intolerance or contraindication evidence
- Specialist consultation notes
- TB testing results and treatment status
- Dosing rationale consistent with compendia/guidelines
Dosing and age verification for GVHD prophylaxis
For GVHD prophylaxis, document the patient's age and verify the prescribed doses on the day before transplant and on Days 5, 14, and 28 do not exceed the age-based mg/kg limits or provide justification if limits are exceeded; see the form's GVHD prophylaxis dosing questions for the specific thresholds.
- Document patient age
- Confirm doses do not exceed age-based mg/kg limits or provide justification
Continuation clinical response documentation
For continuation requests, provide objective measures demonstrating maintained or improved clinical response, such as joint counts, functional ability assessments, and percent improvement in signs/symptoms (e.g., tender/swollen joint counts, pain, or disability).
- Number of affected/swollen/tender joints
- Functional ability measures
- Percent improvement from baseline (e.g., ≥20%)
Form background and definitions
The purpose of the precertification form is to document and justify medical necessity for Orencia across the listed indications by collecting indication‑specific information (diagnosis codes, prescriber specialty or consultation, prior therapy trials or intolerance, and dosing supported by compendia/guidelines) and by ensuring safety and appropriate administration. Safety and administration elements captured include questions about tuberculosis (TB) testing within 6 months with PPD/IGRA/chest x‑ray and results, infusion/administration safety screening (need for outpatient hospital setting due to prior severe infusion adverse events, venous access issues, behavioral/physical/cognitive impairments, or medical instability), and confirmation of specialist involvement for oncology/hematology or rheumatology as applicable.
Document revision history
CURRENT status: Precertification form for Orencia (abatacept) injectable medication used by Aetna to collect patient, prescriber, dispensing, dosing, diagnosis, and clinical information for start or continuation of therapy across multiple indications (RA, PsA, pJIA, GVHD prophylaxis, chronic GVHD, immune checkpoint inhibitor‑related toxicity). No dated revisions were provided in the brief; form content captures required items such as dosing, prior therapy trials, specialist consultation, TB testing, infusion safety, administration CPT codes, and indication‑specific checklists and age‑based GVHD dosing limits.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.